IMN
Apr 17, 2026
Shaping the Future of Idiopathic Membranous Nephropathy Treatment: Breakthroughs in Targeted Therapies
Summary The epidemiological landscape of IMN highlights a substantial disease burden across the seven major markets. According to DelveInsight’s analysis, IMN accounted for approximately 69,000 prevalent cases in 2025, within a broader pool of nearly 87,000 membranous nephropathy cases. This indicates that IMN ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
